XW LABORATORIES
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
FDA Grants Orphan Drug Designation to XW Laboratories' XWL-008 for the Treatment of Patients with Narcolepsy 2019-06-24 17:00
XW Labs Appoints Clinical Development Veteran Dr. Daniel Canafax as Chief Medical Officer 2018-09-10 17:00
XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment 2018-03-12 17:00
XW Labs Initiates First-in-Human Phase I Study for Novel Narcolepsy Treatment 2018-03-12 17:00
XW Labs secures over $17M Series B financing led by Elements Capital and WI Harper 2017-09-20 17:00
XW Labs Announces Exclusive Licensing Agreement with University of Pittsburgh to Develop Novel Mitochondria-Targeting Compounds 2017-03-06 18:00
1